In this study, CD5 expression in CAR-T cells occurred after Dox withdrawal, leading to improved and prolonged antitumor ability against CD5+ T-ALL cell lines Jurkat and CCRF-CEM in vitro, as well as the Jurkat mouse model in vivo (62). This evidence concerns the gene CD5 and acute lymphoblastic leukemia.